Pfizer creates deadline for Trump drug plan

Pfizer Inc. (NYSE:PFE) Chairman and CEO Ian Read has turned President Donald Trump’s fury over drug price increases into an opportunity to create a de facto deadline for the Trump administration to implement its drug pricing blueprint. At the same time, Read seems to have opened the door for pharma companies to negotiate drug prices with the White House.

Read also seized control, at least temporarily, over the industry’s response to the administration’s drug price blueprint by personally

Read the full 782 word article

User Sign In